drugset / Trial / NCT05093608
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
Phase 1
Terminated
2 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find out if the oral drug Selinexor taken along with bevacizumab and atezolizumab is effective in treating advanced Hepatocellular Carcinoma.
Timeline
- Start
- 2021-11-03
- Primary completion
- 2022-10-12
- Completion
- 2022-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 12000 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |